Abstract
Breast cancers often produce tumor marker CA15.3 which can be estimated through immunoassays available commercially. So, the aim of this study is to asses the clinical utility of this tumor marker test for daily practice. The utility of measuring CA15-3 levels for breast cancer patients remains controversial. The ASCO and the NCCN guidelines do not currently recommend the use of serum CA15-3 for breast cancer screening and directing treatment post-operative surveillance Metastatic disease (ASCO, NCCN, EGTM, ESMO) and monitoring treatment response. There were limitations to utility in clinical practice. Further prospective studies will be essential for the validation of these results in our own clinical setting.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Bioscience and Biochemistry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
